 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Hester Biosciences announced that the 36th Annual General Meeting (AGM) of the company will be held on 20 September 2023.

Hester Biosciences to conduct AGM

Hester Biosciences has fixed 13 September 2023 as record date for final dividend. The dividend will be paid on or after 25 September 2023. 

Hester Biosciences fixes record date for final dividend 

Hester Bio Standalone June 2023 Net Sales at Rs 80.35 crore, up 59.01% Y-o-Y

Hester Bio Standalone March 2023 Net Sales at Rs 60.70 crore, up 20.79% Y-o-Y

ICICI Direct recommended hold rating on Hester Biosciences with a target price of Rs 1830 in its research report dated February 02, 2023.

Hold Hester Biosciences; target of Rs 1830: ICICI Direct

Hester Bio Consolidated December 2022 Net Sales at Rs 74.94 crore, up 34.58% Y-o-Y

Hester Bio Standalone December 2022 Net Sales at Rs 70.77 crore, up 31.06% Y-o-Y

In an exchange filing made during market hours today, the vaccine manufacturing company said that it has signed an agreement towards receiving indigenously developed technology from Indian Council of Agricultural Research National Institute of High Security Animal Diseases (ICAR-NIHSAD), for the development and commercialization of the low pathogenic avian influenza (H9N2 strain) inactivated vaccine for poultry.Low pathogenic avian influenza H9N2 strain causes comorbidity in poultry flocks throughout the year, leading to huge economic losses to the poultry farmers. The disease generally has low mortality rate up to 6% but can increase significantly in the presence of other infections. It could also lead to an irreversible egg production drop (up to 50%) in layer birds and a performance loss in broilers.This indigenously developed inactivated H9N2 vaccine for poultry is developed using a local isolate, thereby ensuring that the vaccine is made from the local strain and not by importing any exotic strain.The huge poultry population in India is a key source of livelihood for rural India. Until date, India had no vaccine available for Avian Influenza despite of periodic outbreaks across the country. These factors make this vaccine as having a significant commercial potential,” the company said in a statement.Hester has plans to launch this Vaccine by the end of 2023 after completing the required field studies and obtaining regulatory approvals.Besides supplying the vaccine within India, Hester intends to export this vaccine to African and Asian countries through Hesters own distribution network, where the demand for this vaccine has already been established.Hester is one of the leading poultry and animal healthcare companies in India. It is the second largest poultry vaccine manufacturer in India. It currently has a 75% market share in PPR vaccines for Sheep and Goat, across the world. In addition, the company has a health products portfolio comprising of therapeutics, feed supplements and biosecurity.The companys standalone net profit tumbled 12.1% to Rs 10.35 crore despite of 27.2% jump in net sales to Rs 72 crore in Q2 FY23 over Q2 FY22.

HesterBio gains on acquiring technology for H9N2 avian influenza virus vaccine from ICAR – NIHSAD

Hester Biosciences has signed an agreement towards receiving indigenously developed technology from Indian Council of Agricultural Research National Institute of High Security Animal Diseases (ICAR-NIHSAD), for the development and commercialization of the Low Pathogenic Avian Influenza (H9N2 strain) Inactivated Vaccine for poultry.The agreement was signed on 27 December 2022 at the office of Agrinnovate India, New Delhi. Agrinnovate is a government entity that acts as an interface between ICAR and the stakeholders in the agriculture sector, which includes technology transfers for vaccine manufacturing in the veterinary sector. Besides supplying the vaccine within India, Hester intends to export this vaccine to African and Asian countries through Hesters own distribution network, where the demand for this vaccine has already been established. The huge poultry population in India is a key source of livelihood for rural India. Until date, India had no vaccine available for Avian Influenza despite of periodic outbreaks across the country. These factors make this vaccine as having a significant commercial potential. 

Hester Biosciences to procure technology from ICAR-NIHSAD for development of H9N2 vaccine for poultry

ICICI Direct recommended hold rating on Hester Biosciences with a target price of Rs 2070 in its research report dated November 08, 2022.

Hold Hester Biosciences; target of Rs 2070: ICICI Direct

Hester Biosciences Ltd. is a holding company, which engages in the manufacture and trade of poultry vaccines and animal health products. It operates through the following segments: Poultry Healthcare and Animal Healthcare. The Poultry Healthcare segment offers vaccines and health products for poultry animals. The Animal Healthcare segment provides vaccines and health products including, dugs, feed supplements, and disinfectants for large animals. The company was founded by Rajiv Dinesh Gandhi on April 29, 1987 and is headquartered in Ahmedabad, India.

Watchers	7
52-Wk Low	1,404.55
52-Wk High	2,095.00

Market Cap	14.15B
Volume (M)	3,038.00
52-Wk High	2,095.00
52-Wk Low	1,404.55

HESTERBIO.NSE Hester Biosciences Ltd

About

Feed

News

Fundamentals